SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
IPO Year: 2020
Exchange: NYSE
Website: sqzbiotech.com
Patient's Clinical, Radiographic and Histologic Results Support Potential Impact of SQZ Investigational Therapeutic Patient Demonstrated Symptomatic Improvement Radiographic Response Observed in Target Lesion Tumor Conversion from Desert to Inflamed Phenotype with 8-Fold Increase in CD8 T Cell Tumor Infiltration and 50-Fold Increase in Tumor PD-L1 Expression Interim Results from Ongoing Phase 1/2 Trial Showed Favorable Safety Data and Investigational Therapy was Generally Well Tolerated Company to Host Conference Call Today at 8:00 a.m. ET SQZ Biotechnologies Company (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today presented
Interim SQZ-PBMC-HPV Results from Ongoing Phase 1/2 Trial Showed Favorable Safety Data and that Therapy was Generally Well Tolerated Oral Presentation at ESMO Immuno-Oncology Congress on December 9 to Focus on Highest-Dose Monotherapy Cohort of SQZ™ APC Candidate Company to Host Conference Call on December 9 at 8:00 a.m. ET SQZ Biotechnologies Company (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced interim results from the highest-dose monotherapy cohort of its ongoing Phase 1/2 clinical trial of SQZ-PBMC-HPV, an investigational cell therapy being evaluated in certain patients with advanced or metastatic Human Papillomavirus
DEFM14A - SQZ Biotechnologies Co (0001604477) (Filer)
PREM14A - SQZ Biotechnologies Co (0001604477) (Filer)
15-12G - SQZ Biotechnologies Co (0001604477) (Filer)
8-K - SQZ Biotechnologies Co (0001604477) (Filer)
EFFECT - SQZ Biotechnologies Co (0001604477) (Filer)
POS AM - SQZ Biotechnologies Co (0001604477) (Filer)
S-8 POS - SQZ Biotechnologies Co (0001604477) (Filer)
10-Q - SQZ Biotechnologies Co (0001604477) (Filer)
8-K - SQZ Biotechnologies Co (0001604477) (Filer)
8-K - SQZ Biotechnologies Co (0001604477) (Filer)
SC 13G/A - SQZ Biotechnologies Co (0001604477) (Subject)
SC 13G/A - SQZ Biotechnologies Co (0001604477) (Subject)
SC 13G/A - SQZ Biotechnologies Co (0001604477) (Subject)
SC 13G/A - SQZ Biotechnologies Co (0001604477) (Subject)
SC 13G/A - SQZ Biotechnologies Co (0001604477) (Subject)
SC 13G/A - SQZ Biotechnologies Co (0001604477) (Subject)
SC 13G/A - SQZ Biotechnologies Co (0001604477) (Subject)
SC 13G/A - SQZ Biotechnologies Co (0001604477) (Subject)
SC 13D/A - SQZ Biotechnologies Co (0001604477) (Subject)
SC 13G/A - SQZ Biotechnologies Co (0001604477) (Subject)
Chief Scientific Officer, Howard Bernstein, M.D., Ph.D., to Become Member of the Company's Board of Directors, Effective October 31, 2022 CSO Responsibilities to be Shared Among Ipsita Roymoulik, Ph.D., Scott Loughhead, Ph.D., and Maisam Dadgar as Senior Leaders of Chemistry, Manufacturing and Controls; Translational Research; and Engineering SQZ Biotechnologies Company (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that Howard Bernstein, M.D., Ph.D., has been appointed to the company's board of directors, effective October 31, 2022. Dr. Bernstein has served as the company's Chief Scientific Officer since July 2015, a
Experienced Biotech Leader and Capital Markets Professional Elevated to Chief Financial Officer from Chief Business Officer Role Appointment Effective July 11, 2022 SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it has appointed Micah Zajic, as the company's Chief Financial Officer, effective immediately. Mr. Zajic has served as the company's Chief Business Officer since October 2020 and brings nearly 20 years of biotechnology and capital markets experience to the role. As CFO, Mr. Zajic will continue to report to the CEO and will lead the company's finance and accounting, business development,
Experienced Drug Developer Brings Over 25 Years of Clinical Development Industry Knowledge Across Oncology, Immunology, and Infectious Disease Appointment Effective June 1st, 2022 SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it has appointed Marshelle Smith Warren, M.D., as Chief Medical Officer. Dr. Warren will report to the CEO and lead the company's clinical development, clinical operations, translational medicine, and regulatory affairs functions. Marshelle has tremendous experience in cell-based therapeutic development and will provide complementary expertise as we seek to rapidly advan
4 - SQZ Biotechnologies Co (0001604477) (Issuer)
4 - SQZ Biotechnologies Co (0001604477) (Issuer)
4 - SQZ Biotechnologies Co (0001604477) (Issuer)
4 - SQZ Biotechnologies Co (0001604477) (Issuer)
4 - SQZ Biotechnologies Co (0001604477) (Issuer)
4 - SQZ Biotechnologies Co (0001604477) (Issuer)
4 - SQZ Biotechnologies Co (0001604477) (Issuer)
4 - SQZ Biotechnologies Co (0001604477) (Issuer)
4 - SQZ Biotechnologies Co (0001604477) (Issuer)
4 - SQZ Biotechnologies Co (0001604477) (Issuer)
Company Received Notice Regarding NYSE Continued Listing Standards Section 802.01B SQZ Biotechnologies Company (NYSE:SQZ) (the "Company" or "SQZ"), focused on unlocking the full potential of cell therapies, today announced that its Board of Directors (the "Board") has approved a 1-for-10 reverse stock split ("reverse split") of its common stock, par value $0.001 per share ("Common Stock"), that is expected to become effective on Thursday, July 6, 2023 at 5:00 p.m. Eastern Time (the "Effective Date"). The Company's common stock is expected to begin trading on a split-adjusted basis on the New York Stock Exchange ("NYSE") on July 7, 2023, under the existing symbol "SQZ" and new CUSIP number
Phase 1 SQZ-AAC-HPV-101 Clinical Trial Resumed Following the Observation of a Confirmed Complete Response in the First Patient in the Lowest-Dose Cohort; Anticipate Data for the Highest-Dose Cohort in the Fourth Quarter of 2023 SQZ® eAPC Phase 1/2 Trial Enrollment on Track; Anticipate Data for the Highest-Dose Monotherapy Cohort in Mid-2023 SQZ Biotechnologies Company (NYSE:SQZ), focused on unlocking the full potential of cell therapies, today reported first quarter 2023 financial results and recent portfolio updates. "The confirmed complete response in our first patient in the AAC trial has brought enthusiasm to our trial sites, and we are encouraged by the positive momentum for e
A confirmed complete response was observed in the first patient in the lowest-dose cohort of the Phase 1 SQZ-AAC-HPV-101 clinical trial Following review and recommendation by the Study Safety Committee, the Company is advancing SQZ-AAC-HPV-101 trial to the highest-dose cohort Strong enrollment rates; Anticipate initial clinical data from the highest-dose cohort in the fourth quarter of 2023 SQZ Biotechnologies Company (NYSE:SQZ), focused on unlocking the full potential of cell therapies, today announced that, according to RECIST 1.1 criteria, a confirmed complete response was observed in the first patient in the lowest-dose cohort of the Phase 1 SQZ-AAC-HPV-101 clinical trial. The co
Strategically Focused Company Structure to Prioritize Clinical Development and Deliver Critical, Clinical-Stage Data SQZ® eAPC Phase 1/2 Trial Enrollment on Track; Anticipate Data for the Highest-Dose Monotherapy Cohort in Mid-2023 Phase 1 SQZ-AAC-HPV-101 Clinical Trial to Continue Following the Recent Observation of a Confirmed Complete Response in the First Patient in the Lowest-Dose Cohort; Anticipate Data for the Highest-Dose Cohort in the Fourth Quarter of 2023 SQZ Biotechnologies Company (NYSE:SQZ), focused on unlocking the full potential of cell therapies, today reported full year 2022 financial results and recent portfolio updates. "The team is focused on our key initiatives
SQZ Biotechnologies (NYSE:SQZ) today announced that on January 18, 2023, it received notice from the New York Stock Exchange (NYSE) indicating that the Company is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company's common stock was less than $1.00 over a consecutive 30 trading-day period. The notice does not result in the immediate delisting of the Company's common stock from the NYSE. The Company plans to notify the NYSE of its intent to cure the stock price deficiency and return to compliance with the NYSE's continued listing standards. Under NYSE rules, the Company has a period of six months from receipt of the NYSE
Designation Represents Potential to Bring Important New Therapy to Patients Earlier Stable Disease Observed in Two Out of Four Evaluable Patients in eAPC Phase 1/2 Trial Including a Pronounced Pharmacodynamic Response in a Patient with Prolonged Stable Disease Interim Results from Ongoing SQZ® eAPC Phase 1/2 Trial Showed Favorable Safety Data and Investigational Therapy was Generally Well Tolerated Median Drug Viability of Greater than 90 Percent for Both SQZ® eAPC and SQZ® APC Clinical Trials SQZ Biotechnologies Company (NYSE:SQZ) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the company's Enhanced Antigen Presenting Cell (
Strategic Reprioritization of Portfolio: Focus on Advancing Second-Generation Cell Therapy Program, Enhanced Antigen Presenting Cells Howard Bernstein, MD, PhD, Former Chief Scientific Officer, Appointed as Interim Chief Executive Office; Armon Sharei, PhD, to step down from role as CEO and member of the Board of Directors Company to Reduce Workforce by Approximately 60%; Initial Cost Saving Measures Expected to Extend Cash Runway Into 2024 SQZ Biotechnologies (NYSE:SQZ) today announced the strategic prioritization of its clinical portfolio to concentrate on the development of its second-generation enhanced Antigen Presenting Cells (eAPC) cell therapy program, focused on HPV16 positive r
Cell Squeeze® Platform Offers Advantages for GMP Engineering of Multiple Cell Types and Reduced Manufacturing Time and Cost through its Point-of-Care System mRNA Constructs Encoding Multiple Linked Antigens Could Allow for a Multiantigen-Specific CD8+ T Cell Response SQZ® eAPCs Contain Five mRNAs Encoding for Proteins Stimulating the Key T Cell Activation Signals to Potentially Mount Potent Immune Response Against Tumors SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, will present preclinical research demonstrating the potential of its Cell Squeeze® technology to multiplex engineer a diverse set of cell types, incl
Published Comprehensive Preclinical Research on SQZ® AAC Platform in Frontiers in Immunology Continued Investigational New Drug-Enabling Activities for SQZ® TAC Platform; Submission Expected in First Half of 2023 with Clinical Batches Intended to be Manufactured on the Company's Point-of-Care System Anticipate Interim Clinical Data for HPV16+ Solid Tumors by the End of 2022 SQZ Biotechnologies (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today reported third quarter 2022 financial results and recent portfolio updates. "I am proud of the SQZ team's accomplishments this quarter, including our publication showcasing the AAC platf
Activating Antigen Carriers (AACs) Shown Preclinically to Activate CD8 T Cells, Increase Their Tumor Infiltration and Drive Tumor Killing Demonstrated Improved Efficacy of AAC Therapy Through Combination with Chemotherapy Agent SQZ Biotechnologies Company (NYSE:SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced the publication of preclinical research on the SQZ® Activating Antigen Carrier (AAC) platform. The data, published in Frontiers in Immunology, demonstrated that the company's Cell Squeeze® platform can be used to generate AACs by engineering red blood cells (RBCs) with antigen and adjuvant that can drive antigen-specific
Gainers SQZ Biotechnologies (NYSE:SQZ) shares increased by 68.1% to $0.45 during Monday's regular session. The current volume of 30.0 million shares is 44863.5% of SQZ Biotechnologies's average full-day volume over the last 100 days (last updated at 13:37 EST). The market value of their outstanding shares is at $13.3 million. Nymox Pharmaceutical (NASDAQ:NYMX) shares rose 31.68% to $0.25. Nymox Pharmaceutical's stock is trading at a volume of 3.3 million shares as of 13:37 EST. This is 5697.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $22.8 million. Ensysce Biosciences (NASDAQ:ENSC) shares increased by 31.11% to $2.36. Tradin
Gainers PolyMet Mining Corp. (NYSE:PLM) shares surged 144% to $1.92 after the company announced Glencore made a non-binding proposal to acquire the company for $2.11 per share. Fresh Vine Wine, Inc. (NYSE:VINE) gained 70.1% to $0.3845. Fresh Vine Wine recently announced the appointment of Hitesh Dheri as Chief Financial Officer and Secretary. Advanced Health Intelligence Ltd. (NASDAQ:AHI) shares jumped 65.1% to $6.32. Advanced Health Intelligence recently announced the implementation of an ADS ratio change. SQZ Biotechnologies Company (NYSE:SQZ) shares gained 46.1% to $0.3944 after declining 11% on Friday. IMAC Holdings, Inc. (NASDAQ:BACK) shares jumped 38.6% to $0.1524. Theralink rec
Gainers SQZ Biotechnologies (NYSE:SQZ) stock moved upwards by 58.5% to $0.43 during Monday's pre-market session. The market value of their outstanding shares is at $12.6 million. IMAC Hldgs (NASDAQ:BACK) stock rose 45.18% to $0.16. The company's market cap stands at $5.2 million. Ra Medical Systems (AMEX:RMED) stock rose 19.56% to $1.1. The company's market cap stands at $5.9 million. Myomo (AMEX:MYO) stock moved upwards by 17.65% to $0.61. The company's market cap stands at $12.7 million. Alvotech (NASDAQ:ALVO) stock increased by 14.98% to $8.9. The company's market cap stands at $2.3 billion. Comera Life Sciences (NASDAQ:CMRA) stock rose 14.17% to $0.56. The market value of their out
Gainers Micromobility.com Inc. (NASDAQ:MCOM) shares surged 60% to $0.18 in pre-market trading. micromobility.com recently reported a strategic realignment to strengthen its financial position and drive profitability. Fortress Biotech, Inc. (NASDAQ:FBIO) shares gained 38.2% to $0.76 in pre-market trading. Urica Therapeutics, a Fortress Biotech subsidiary company, recently disclosed topline data from the Phase 1 clinical trial evaluating dotinurad in healthy volunteers in the United States. IMAC Holdings, Inc. (NASDAQ:BACK) shares rose 35.9% to $0.1495 in pre-market trading. Theralink recently signed definitive merger agreement to be acquired by IMAC Holdings. FLJ Group Limited (NASDAQ:
Gainers Benitec Biopharma Inc. (NASDAQ:BNTC) climbed 104% to $0.4050 after the company announced it received FDA clearance of the IND for BB-301 for the treatment of Oculopharyngeal Muscular Dystrophy. TRxADE HEALTH, Inc. (NASDAQ:MEDS) shares jumped 91.9% to $16.20. TRxADE HEALTH issued correction to press release announcing its anticipated combination with Superlatus, Inc. MoonLake Immunotherapeutics (NASDAQ:MLTX) gained 75% to $45.50 after the company's Phase 2 study for Nanobody sonelokimabint met its primary endpoint in hidradenitis suppurativa. INVO Bioscience, Inc. (NASDAQ:INVO) shares jumped 41% to $0.2327 after dropping 5% on Friday. iMedia Brands, Inc. (NASDAQ:IMBI) gained
Gainers MoonLake (NASDAQ:MLTX) shares increased by 80.5% to $46.71 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 billion. INVO Bioscience (NASDAQ:INVO) shares rose 50.06% to $0.25. The company's market cap stands at $3.4 million. Femasys (NASDAQ:FEMY) stock rose 36.63% to $0.84. The company's market cap stands at $11.0 million. Benitec Biopharma (NASDAQ:BNTC) shares increased by 35.77% to $0.27. The market value of their outstanding shares is at $7.5 million. SQZ Biotechnologies (NYSE:SQZ) shares moved upwards by 30.29% to $0.52. The company's market cap stands at $15.3 million. CollPlant Biotechnologies (NASDAQ:CLGN) shares increased by 19
Gainers TRxADE HEALTH, Inc. (NASDAQ:MEDS) shares surged 84.1% to $15.54 in pre-market trading after jumping over 15% on Friday. Superlatus, Inc. signed a binding letter of intent to be acquired by TRxADE HEALTH. Digital Media Solutions, Inc. (NYSE:DMS) shares gained 71.4% to $0.5750 in pre-market trading after gaining around 5% on Friday. Digital Media Solutions recently reported slightly worse-than-expected Q1 sales results. INVO Bioscience, Inc. (NASDAQ:INVO) shares rose 70.8% to $0.2819 in pre-market trading after dropping 5% on Friday. SQZ Biotechnologies Company (NYSE:SQZ) shares rose 40% to $0.56 in pre-market trading after dropping around 23% on Friday. Eco Wave Power Global AB
Gainers Conformis (NASDAQ:CFMS) stock moved upwards by 90.6% to $2.21 during Friday's pre-market session. The market value of their outstanding shares is at $16.5 million. OncoSec Medical (NASDAQ:ONCS) shares rose 84.82% to $0.39. The company's market cap stands at $2.3 million. Surgalign Holdings (NASDAQ:SRGA) stock increased by 58.8% to $0.32. The market value of their outstanding shares is at $2.9 million. SCWorx (NASDAQ:WORX) stock rose 32.14% to $0.47. The market value of their outstanding shares is at $6.1 million. Renalytix (NASDAQ:RNLX) stock rose 12.37% to $2.38. The market value of their outstanding shares is at $111.5 million. SQZ Biotechnologies (NYSE:SQZ) stock rose 11.9%
Company Received Notice Regarding NYSE Continued Listing Standards Section 802.01BSQZ Biotechnologies Company (NYSE:SQZ) (the "Company" or "SQZ"), focused on unlocking the full potential of cell therapies, today announced that its Board of Directors (the "Board") has approved a 1-for-10 reverse stock split ("reverse split") of its common stock, par value $0.001 per share ("Common Stock"), that is expected to become effective on Thursday, July 6, 2023 at 5:00 p.m. Eastern Time (the "Effective Date"). The Company's common stock is expected to begin trading on a split-adjusted basis on the New York Stock Exchange ("NYSE") on July 7, 2023, under the existing symbol "SQZ" and new CUSIP number 784
SQZ Biotechnologies (NYSE:SQZ) reported quarterly losses of $(0.60) per share which missed the analyst consensus estimate of $(0.51) by 17.65 percent. This is a 20 percent increase over losses of $(0.75) per share from the same period last year.